dutasteride + tamsulosin (Jalyn / Combodart / Duodart)

The silent signal is tadalafil counterbalancing tamsulosin induced ejaculatory dysfunction.

Zhang Tao T, Yu Maobin M

[Modern treatment of androgenetic alopecia].

Rózsa Petra P, Kemény Lajos L, Gyulai Rolland R

Androgenetic alopecia is the most common hair loss, characterized by a chronic and progressive course and a significant psychosocial burden. The aim of this study was to provide a comparative analysis of current international guidelines and expert consensus statements on the treatment of androgenetic alopecia and to summarize their applicability in clinical practice. A literature search was performed in the PubMed database to identify English-language guidelines and expert recommendations published between 2015 and 2025. The included documents were analyzed narratively and compared based on therapeutic approaches. Conventional treatments, including topical minoxidil and 5-alpha-reductase inhibitors, remain the cornerstone of therapy. More recent recommendations increasingly support the use of low-dose oral minoxidil and dutasteride; however, their position varies across guidelines. The role of procedural therapies also differs, mainly due to limited evidence. Differences between recommendations are primarily driven by variability in levels of evidence and the evolving new therapies. In clinical practice, an individualized, multimodal treatment strategy combined with regular follow-up is essential. The management of androgenetic alopecia is a rapidly evolving field requiring personalized therapeutic decisions. In clinical practice, a personalized combined treatment strategy and regular follow-up are of paramount importance. Orv Hetil. 2026; 167(35): 1385-1393.

Tamsulosin versus tamsulosin plus tolterodine for the treatment of distal ureteral stones.

Mohseni-Rad Hamed H, Imani Geshlaghchayi Houshyar H, Iranpour Sohrab S

This study aimed to compare the efficacy of tamsulosin monotherapy versus tamsulosin combined with tolterodine for facilitating the expulsion of distal ureteral stones. A prospective, randomized controlled trial was conducted between 2022 and 2023 at the Urology Clinic of Imam Reza Hospital, Ardabil. A total of 120 patients diagnosed with distal ureteral stones (4-10 mm in size) were randomized into two groups: Group A received 0.4 mg tamsulosin daily, and Group B received 0.4 mg tamsulosin daily plus 2 mg tolterodine twice daily. Treatment duration was up to 4 weeks. Primary outcomes included stone expulsion rate and expulsion time. Secondary outcomes comprised pain control (visual analog scale, VAS), analgesic requirement, and incidence of side effects. The two groups were comparable at baseline in terms of demographic and stone characteristics. The stone expulsion rate was significantly higher in Group B (tamsulosin + tolterodine) at 83.3% (50/60) compared to Group A (tamsulosin alone) at 66.7% (40/60) (p = 0.03). The mean stone expulsion time was also significantly shorter in Group B (10.5 ± 3.2 days) compared to Group A (14.8 ± 4.1 days) (p < 0.001). Patients in Group B reported lower mean pain scores (VAS) and required less rescue analgesia. The incidence of adverse effects was comparable between the groups, with dry mouth being slightly more common in Group B. The combination of tamsulosin and tolterodine demonstrated superior efficacy in terms of stone expulsion rate and reduced expulsion time for distal ureteral stones compared to tamsulosin monotherapy. This combination therapy may offer a more effective medical expulsive therapy option for patients with distal ureteral calculi.

Lurasidone-Associated Urinary Retention in a Patient With Bipolar Affective Disorder: A Case Report.

Ridge Andrew A, Williams Kyle K, Seidel Bastian B

Atypical antipsychotics, including lurasidone, are increasingly prescribed due to their perceived lower risk of side effects. We present the case of a 65-year-old woman with longstanding BPAD who developed symptoms of urinary retention (UR), confirmed on bladder ultrasound, soon after beginning lurasidone monotherapy for bipolar affective disorder (BPAD) management. Despite dose reduction and addition of tamsulosin, symptoms of UR persisted and only resolved with cessation of lurasidone. The causal relationship between lurasidone and UR was assessed using the Naranjo Adverse Drug Reaction (ADR) Probability Scale, yielding a score of 8, indicating a highly 'probable' ADR. A literature review revealed only two prior reports of lurasidone-associated UR, highlighting the rarity of this presentation. This case underscores the need for clinicians to remain vigilant for UR in patients prescribed lurasidone, or other atypical antipsychotics, despite their generally favourable side effect profile. Early recognition and management are critical to prevent complications and ensure appropriate ongoing treatment of BPAD.